The Era of Rapid-Acting Antidepressants: Clinical Insights Into Ketamine, Esketamine, and Scopolamine
Background: Treatment-resistant depression (TRD) represents a major clinical challenge, being associated with high morbidity, increased suicide risk, and substantial socioeconomic burden. The need for rapidly acting interventions has driven the development of rapid-acting antidepressants (RAADs), such as ketamine, eske...